Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4680181 | 0.89 | CNR1 (0.52) | CNR1SMN1; SMN2L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL5754413 | 0.88 | CNR1 (0.50) | CNR1SMN1; SMN2L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL4681021 | 0.87 | CNR1 (0.57) | CNR1SMN1; SMN2L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL4247678 | 0.87 | CNR1 (0.57) | CNR1SMN1; SMN2L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL4677242 | 0.82 | CNR1 (0.46) | CNR1SMN1; SMN2L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL4681335 | 0.82 | CNR1 (0.51) | CNR1SMN1; SMN2L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL4247679 | 0.82 | CNR1 (0.57) | CNR1L3MBTL1KDM4ELMNADHODH | |
| SCHEMBL4676300 | 0.80 | SMN1; SMN2 (0.52) | CNR1SMN1; SMN2L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL4783347 | 0.79 | CNR1 (0.48) | CNR1SMN1; SMN2L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL4678461 | 0.78 | CNR1 (0.47) | CNR1SMN1; SMN2L3MBTL1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1638953-B1 | 3-SUBSTITUTED 5,6-DIARYL-PYRAZINE-2-CARBOXAMIDE AND -2-SULFONAMIDE DERIVATIVES AS CB1 MODULATORS | ASTRAZENECA AB (SE) | 2008-08-27 | — | — | EP | disclosed |
| US-20070093484-A1 | 3-Substituted 5,6-diaryl-pyrazine-2-carboxamide and -2-sulfonamide derivatives as cb1 modulators | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | US | disclosed |
| EP-1638953-A1 | 3-SUBSTITUTED 5,6-DIARYL-PYRAZINE-2-CARBOXAMIDE AND -2-SULFONAMIDE DERIVATIVES AS CB1 MODULATORS | AstraZeneca AB (SE) | 2006-03-29 | — | — | EP | disclosed |
| WO-2004111034-A1 | 3-SUBSTITUTED 5,6-DIARYL-PYRAZINE-2-CARBOXAMIDE AND -2-SULFONAMIDE DERIVATIVES AS CB1 MODULATORS | ASTRAZENECA AB (SE) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093484-A1 | 3-Substituted 5,6-diaryl-pyrazine-2-carboxamide and -2-sulfonamide derivatives as cb1 modulators | CNR2, CNR1, FAAH | CNR1 2/4885SMN1; SMN2 1244/4885L3MBTL1 4558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.